High expression of microRNA-126 relates to favorable prognosis for colon cancer patients

被引:12
作者
Selven, Hallgeir [1 ,2 ]
Busund, Lill-Tove Rasmussen [3 ,4 ]
Andersen, Sigve [1 ,2 ]
Bremnes, Roy M. [1 ,2 ]
Kilvaer, Thomas Karsten [1 ,2 ]
机构
[1] Univ Hosp North Norway, Dept Oncol, N-9038 Tromso, Norway
[2] UiT Arctic Univ Norway, Dept Clin Med, Tromso, Norway
[3] UiT Arctic Univ Norway, Dept Med Biol, Tromso, Norway
[4] Univ Hosp North Norway, Dept Clin Pathol, Tromso, Norway
关键词
STAGE-II; ADJUVANT THERAPY; MIR-126; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; SURVIVAL; GROWTH;
D O I
10.1038/s41598-021-87985-3
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
miR-126 has been identified both as a tumor suppressor and an oncogene in different types of cancer. The aim of this study was to investigate the prognostic impact of miR-126-expression in colon cancer patients. Tumor tissue from 452 patients operated for stage I-III colon cancer was retrospectively collected and tissue microarrays were constructed. miR-126 expression was evaluated by in situ hybridization and analyzed using digital pathology. To isolate the compartment specific contribution of miR-126, tumor and adjacent tumor stroma were considered separately. In univariate analyses, high expression of miR-126 in tumor and stroma was related to increased disease-specific survival (p<0.001 and p=0.005, respectively). In multivariate analyses, high miR-126 expression in tumor remained a significant independent predictor of improved disease-specific survival (HR=0.42, CI 0.23-0.75, p=0.004). Within different TNM-stages there was a tendency towards the same results, but with statistically significant results in stage II only (p=0.007). High expression of miR-126 is an independent positive prognostic factor in stage I-III colon cancer. This finding may be used to identify patients in need of adjuvant chemotherapy.
引用
收藏
页数:10
相关论文
共 30 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]   Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study [J].
Andre, Thierry ;
de Gramont, Armand ;
Vernerey, Dewi ;
Chibaudel, Benoist ;
Bonnetain, Franck ;
Tijeras-Raballand, Annemilai ;
Scriva, Aurelie ;
Hickish, Tamas ;
Tabernero, Josep ;
Van Laethem, Jean Luc ;
Banzi, Maria ;
Maartense, Eduard ;
Shmueli, Einat ;
Carlsson, Goran U. ;
Scheithauer, Werner ;
Papamichael, Demetris ;
Moeehler, Marcus ;
Landolfi, Stefania ;
Demetter, Pieter ;
Colote, Soudhir ;
Tournigand, Christophe ;
Louvet, Christophe ;
Duval, Alex ;
Flejou, Jean-Francois ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) :4176-+
[3]   QuPath: Open source software for digital pathology image analysis [J].
Bankhead, Peter ;
Loughrey, Maurice B. ;
Fernandez, Jose A. ;
Dombrowski, Yvonne ;
Mcart, Darragh G. ;
Dunne, Philip D. ;
McQuaid, Stephen ;
Gray, Ronan T. ;
Murray, Liam J. ;
Coleman, Helen G. ;
James, Jacqueline A. ;
Salto-Tellez, Manuel ;
Hamilton, Peter W. .
SCIENTIFIC REPORTS, 2017, 7
[4]   Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature [J].
Bockelman, Camilla ;
Engelmann, Bodil E. ;
Kaprio, Tuomas ;
Hansen, Torben F. ;
Glimelius, Bengt .
ACTA ONCOLOGICA, 2015, 54 (01) :5-16
[5]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[6]   High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer [J].
Bremnes, RM ;
Veve, R ;
Gabrielson, E ;
Hirsch, FR ;
Baron, A ;
Bemis, L ;
Gemmill, RM ;
Drabkin, HA ;
Franklin, WA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2417-2428
[7]  
Brierley JD, 2016, TNM Classification of Malignant Tumours, V8th
[8]  
Cancer registry of Norway, 2019, CANC INCIDENCE MORTA
[9]   Prognostic significance of miR-126 in various cancers: a meta-analysis [J].
Dong, Yuanli ;
Fu, Chengrui ;
Guan, Hui ;
Zhang, Zicheng ;
Zhou, Tao ;
Li, Baosheng .
ONCOTARGETS AND THERAPY, 2016, 9 :2547-2555
[10]   Deregulation of miR-126 expression in colorectal cancer pathogenesis and its clinical significance [J].
Ebrahimi, Faeza ;
Gopalan, Vinod ;
Wahab, Riajul ;
Lu, Cu-Tai ;
Smith, Robert Anthony ;
Lam, Alfred King-Yin .
EXPERIMENTAL CELL RESEARCH, 2015, 339 (02) :333-341